Antithrombin III Levels and Outcomes Among Patients With Trauma.

Autor:	Farrell DH; Donald D. Trunkey Center for Civilian and Combat Casualty Care, Oregon Health & Science University, Portland., McConnell KM; Donald D. Trunkey Center for Civilian and Combat Casualty Care, Oregon Health & Science University, Portland., Zilberman-Rudenko J; Donald D. Trunkey Center for Civilian and Combat Casualty Care, Oregon Health & Science University, Portland., Behrens B; Donald D. Trunkey Center for Civilian and Combat Casualty Care, Oregon Health & Science University, Portland., Mcloud S; Donald D. Trunkey Center for Civilian and Combat Casualty Care, Oregon Health & Science University, Portland., Cook MR; Donald D. Trunkey Center for Civilian and Combat Casualty Care, Oregon Health & Science University, Portland., Martin D; Division of Acute Care Surgery, Department of Surgery, University of Minnesota, Minneapolis., Yonge JD; Donald D. Trunkey Center for Civilian and Combat Casualty Care, Oregon Health & Science University, Portland., Underwood SJ; Donald D. Trunkey Center for Civilian and Combat Casualty Care, Oregon Health & Science University, Portland., Lape DE; Donald D. Trunkey Center for Civilian and Combat Casualty Care, Oregon Health & Science University, Portland., Goodman A; Donald D. Trunkey Center for Civilian and Combat Casualty Care, Oregon Health & Science University, Portland., Schreiber MA; Donald D. Trunkey Center for Civilian and Combat Casualty Care, Oregon Health & Science University, Portland.
Jazyk:	angličtina
Zdroj:	JAMA network open [JAMA Netw Open] 2024 Aug 01; Vol. 7 (8), pp. e2427786. Date of Electronic Publication: 2024 Aug 01.
DOI:	10.1001/jamanetworkopen.2024.27786
Abstrakt:	Importance: Patients with trauma exhibit a complex balance of coagulopathy manifested by both bleeding and thrombosis. Antithrombin III is a plasma protein that functions as an important regulator of coagulation. Previous studies have found a high incidence of antithrombin III deficiency among patients with trauma. Objective: To assess whether changes in antithrombin III activity are associated with thrombohemorrhagic complications among patients with trauma. Design, Setting, and Participants: This cohort study was conducted from December 2, 2015, to March 24, 2017, at a level I trauma center. A total of 292 patients with trauma were followed up from their arrival through 6 days from admission. Data, including quantification of antithrombin III activity, were collected for these patients. Thromboprophylaxis strategy; hemorrhage, deep vein thrombosis (DVT), and pulmonary embolism screenings; and follow-up evaluations were conducted per institutional protocols. Data analyses were performed from September 28, 2023, to June 4, 2024. Main Outcomes and Measures: The primary study outcome measurements were associations between antithrombin III levels and outcomes among patients with trauma, including ventilator-free days, hospital-free days, intensive care unit (ICU)-free days, hemorrhage, venous thromboembolic events, and mortality. Results: The 292 patients had a mean (SD) age of 54.4 (19.0) years and included 211 men (72.2%). Patients with an antithrombin III deficiency had fewer mean (SD) ventilator-free days (27.8 [5.1] vs 29.6 [1.4]; P = .0003), hospital-free days (20.3 [8.2] vs 24.0 [5.7]; P = 1.37 × 10-6), and ICU-free days (25.7 [4.9] vs 27.7 [2.3]; P = 9.38 × 10-6) compared with patients without a deficiency. Antithrombin III deficiency was also associated with greater rates of progressive intracranial hemorrhage (21.1% [28 of 133] vs 6.3% [10 of 159]; P = .0003) and thrombocytopenia (24.8% [33 of 133] vs 5.0% [8 of 159]; P = 1.94 × 10-6). Although antithrombin III deficiency was not significantly associated with DVT, patients who developed a DVT had a more precipitous decrease in antithrombin III levels that were significantly lower than patients who did not develop a DVT. Conclusions and Relevance: In this cohort study of patients with trauma, antithrombin III deficiency was associated with greater injury severity, increased hemorrhage, and increased mortality, as well as fewer ventilator-free, hospital-free, and ICU-free days. Although this was an associative study, these data suggest that antithrombin III levels may be useful in the risk assessment of patients with trauma.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu